Form 8-K - Current report:
SEC Accession No. 0001520138-21-000754
Filing Date
2021-12-01
Accepted
2021-12-01 09:15:48
Documents
16
Period of Report
2021-11-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT bivi-20211130_8k.htm   iXBRL 8-K 48377
2 EXHIBIT 10.1 bivi-20211130_8kex10z1.htm EX-10.1 323496
3 EXHIBIT 10.2 bivi-20211130_8kex10z2.htm EX-10.2 194622
4 EXHIBIT 10.3 bivi-20211130_8kex10z3.htm EX-10.3 121440
5 EXHIBIT 99.1 bivi-20211130_8kex99z1.htm EX-99.1 9003
  Complete submission text file 0001520138-21-000754.txt   995985

Data Files

Seq Description Document Type Size
6 XBRL PRESENTATION FILE bivi-20211130_pre.xml EX-101.PRE 22373
7 XBRL SCHEMA FILE bivi-20211130.xsd EX-101.SCH 3046
8 XBRL LABEL FILE bivi-20211130_lab.xml EX-101.LAB 34240
9 EXTRACTED XBRL INSTANCE DOCUMENT bivi-20211130_8k_htm.xml XML 3612
Mailing Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404
Business Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404 310-444-4300
BIOVIE INC. (Filer) CIK: 0001580149 (see all company filings)

EIN.: 462510769 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39015 | Film No.: 211461585
SIC: 2834 Pharmaceutical Preparations